Working capital intensity remains high
IPO proceeds of ₹20 crore are earmarked for working capital, indicating structurally high inventory and receivable requirements.
AAKAARMEDICALTECHNOLOGIE / Q4-FY26 / risks
Keep the risk register visible.
Aakaar Medical Technologies · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
H2 margin sustainability questioned
Analyst asked if 26% EBITDA margin in H2 was sustainable or due to one-off lower conference costs; management acknowledged H2 typically has lower expenses.
Deferred demand normalization risk
H2 revenue growth of 64% HoH may partly reflect deferred demand from H1 credit tightening; FY27 growth could normalize.
Dependence on new product launches
Growth hinges on successful ramp-up of new products (Latigo, VM exosomes) which faced regulatory delays; any further delays could impact revenue.